Skip to main content

Nadir PSA is a Strong Predictor of Treatment Outcome in Intermediate and High Risk Localized Prostate Cancer Patients Treated by Definitive External Beam Radiotherapy and Androgen Deprivation.

32 stars
Khader
Jamal
Radiation Oncology
King Hussein Cancer Center
Amman
Amman
Jordan
Show all authors
GEARA
FADY
RADIATION ONCOLOGY
The Naef K. Basile Cancer Institute at the American University of Beirut
Beirut
Beirut
Lebanon
Khuli
Raja
Urology
The Naef K. Basile Cancer Institute at the American University of Beirut
Beirut
Beirut
Lebanon
Bulbul
Muhammad
Urology
The Naef K. Basile Cancer Institute at the American University of Beirut
Beirut
Beirut
Lebanon
Sarhan
Nasim
Radiation Oncology
King Hussein Cancer Center
Amman
Amman
Jordan
Sharafeddine
Maya
Medical Oncology
The Naef K. Basile Cancer Institute at the American University of Beirut
Beirut
Beirut
Jordan
Shamseddine
Ali
Medical Oncology
The Naef K. Basile Cancer Institute at the American University of Beirut
Beirut
Beirut
Lebanon

Tabs

Speciality: 
Radiotherapy
Keywords: 
Intermediate and High Risk Localized Prostate Cancer, Nadir PSA, External radiotherapy, Hormonal therapy